TABLE 2.
Routine immunophenotyping for the percentages of B (CD19+), T (CD3+), T-helper (CD3+ CD4+), T-suppressor/cytotoxic (CD3+ CD8+), and NK (CD3− CD16+ CD56+) lymphocytes in newly diagnosed untreated JDM patients and age-related healthy control children
| Group | Age (n) | % CD3+ | % CD4+ | % CD8+ | % CD19+ | % CD16+ CD56+ |
|---|---|---|---|---|---|---|
| Healthy controla | 7.9 ± 0.6 (12) | 71 ± 2 | 42 ± 2 | 26 ± 1 | 19 ± 1 | 10 ± 1 |
| JDM patients | 5.9 ± 0.9 (10) (P = 0.07) | 64 ± 3 (P = 0.05) | 43 ± 3 (P = 0.9) | 21 ± 1 (P = 0.01) | 30 ± 3 (P = 0.0017) | 7 ± 2 (P = 0.019) |
a
Includes only healthy children less than 10 years of age.
b
P values indicate the level of significance of the difference between the healthy control group and the JDM patient group. P values were calculated using the Wilcoxon rank sum test for nonparametric data.